Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$525.99 - $1.21K
Next Earnings Date
Apr 29 2025
Next Earnings Date
Apr 29 2025
Latest price
Market Cap | $62.91B |
EV | $47.94B |
Shares Outstanding | 107.02M |
Beta | 0.44 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $856.75 |
P/E 2025E | 14.70x |
P/Revenue 2025E | 4.42x |
Revenue | -4.00% |
EPS | -15.10% |
Operating Cash Flow | -14.50% |
Free Cash Flow | -17.50% |
Revenue | 5.30% |
EPS | 4.70% |
Operating Cash Flow | 7.10% |
Free Cash Flow | 17.70% |
Gross Margin 2025E | 87.40% |
Net Profit Margin 2025E | 26.02% |
ROE 2025E | 14.90% |
ROCE 2024 | 15.95% |
DPS 2025E | $2.83 |
Payout Ratio 2025E | 7.08% |
Div. Yield 2025E | 0.47% |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Regeneron Pharmaceuticals, Inc.
REGN
Sector
Healthcare
Industry
Biotechnology
CEO
Schleifer, Leonard
Employees
15,106
Website
www.regeneron.comIPO Date
1991-04-02
Headquarters
777 Old Saw Mill River Road, Tarrytown, New York, 10591-6707, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved